Clinical Trial: Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07072234) titled 'Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma' on July 09.

Brief Summary: Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.

Study Start Date: Jan. 01, 2026

Study Type: INTERVENTIONAL

Condition: Clear Cell Carcinoma Phase 1 Growth Factor

Intervention: DRUG: Lymphodepleting chemotherapy

Given by IV

DRUG: Dexamethasone

Given PO

DRUG: Fludarabine

Given by IV

DRUG: Cyclophosphamate

Given by IV

DRUG: TGFBR-2 KO CD70 CAR NK

Given by IV

Recruitment Status: NOT_YET_RECRUITING

Sp...